Cartesian SEC Filings

Cartesian Therapeutics (RNAC) reported initial Phase 2 data for Descartes-08 in systemic lupus erythematosus and outlined plans to expand the program into myositis. In the open-label SLE study, 100% of participants who reached Month 3 follow-up (n=3) achieved LLDAS, with disease remission (DORIS) in two of three. Safety observations noted outpatient administration without preconditioning, mostly mild adverse events, and no CRS or ICANS.

Correlative biomarkers showed a statistically significant (p<0.01) decline in proinflammatory cytokines (IL7, IL10, CCL20, ST1A1) and decreased plasmacytoid dendritic cells, supporting expansion into myositis. The planned randomized, double-blind, placebo-controlled myositis Phase 2 will enroll up to 50 patients, use six weekly outpatient infusions, assess a Week 24 primary endpoint, and include an interim analysis after ten patients reach the endpoint. An IND is planned by the end of 2025, with trial start targeted for the first half of 2026. The company will pause further SLE work on Descartes-08 and development of Descartes-15 to prioritize Descartes-08 in myasthenia gravis (Phase 3) and myositis.

Cartesian Therapeutics (RNAC) filed its Q3 2025 10‑Q, reporting operating progress and updated financials. Cash and cash equivalents were $143.4 million ($145.1 million including restricted) and management states this will fund current planned operations for at least the next 12 months.

Total revenue was $0.5 million in the quarter and $1.9 million year‑to‑date, primarily from grants. Research and development expense was $13.8 million in Q3 ($43.3 million YTD), and general and administrative was $7.7 million in Q3 ($23.3 million YTD). The company recorded a Q3 net loss of $35.9 million and a year‑to‑date net loss of $37.7 million, reflecting operating spend and non‑cash fair‑value changes.

The contingent value right liability decreased to $369.0 million from $395.5 million, with $7.8 million distributed in March 2025 per the CVR terms. Shares outstanding were 26,003,606 as of October 31, 2025. The company remains focused on clinical‑stage cell therapies for autoimmune diseases.

Cartesian Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2025. The company furnished a press release with details as Exhibit 99.1 to a Form 8-K.

The Item 2.02 information, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference except as expressly stated. The filing lists the company’s common stock trading on The Nasdaq Stock Market LLC under the symbol RNAC.

Cartesian Therapeutics (RNAC) announced board leadership changes and a bylaws update. On October 29, 2025, Carrie S. Cox resigned from the Board, effective immediately, following her appointment as Executive Chair of another public company. The company stated her resignation was not the result of a disagreement regarding operations, policies, or practices.

The Board appointed Carsten Brunn, Ph.D., as Chairman; named Patrick Zenner, M.B.A., as Lead Independent Director; and appointed Kemal Malik, M.B.B.S., as Chair of the Compensation Committee. Dr. Brunn will not receive additional pay for serving as Chairman, while Mr. Zenner and Dr. Malik will be compensated per the Non-Employee Director Compensation Program.

Also on October 29, 2025, the Board approved amended and restated bylaws to include references to the Lead Independent Director role. On October 30, 2025, the company furnished a press release announcing Dr. Brunn’s appointment.

Cartesian Therapeutics (RNAC) reported a Form 4 for its Chief Accounting Officer, June Ann Seymour, documenting an equity award. On 10/27/2025, Seymour received an employee stock option50,000 shares at an exercise price of $8.85 per share, expiring on 10/27/2035.

The option vests as to 25% on 10/27/2026, with the remaining underlying shares vesting in three equal annual installments so that all shares are fully vested on 10/27/2029. The filing lists ownership of the derivative security as Direct (D) with 50,000 derivative securities beneficially owned following the reported transaction.

Cartesian Therapeutics, Inc. (RNAC) filed a Form 3 initial statement of beneficial ownership for officer June Ann Seymour, who serves as Chief Accounting Officer. The filing states that no securities are beneficially owned.

The date of the event requiring the statement is 10/27/2025. The form was filed by one reporting person and signed by /s/ Matthew Bartholomae as attorney-in-fact pursuant to an Exhibit 24 power of attorney.

Cartesian Therapeutics (RNAC) eliminated its Chief Scientific Officer role and provided a termination without cause notice to Christopher Jewell, Ph.D., effective November 14, 2025. The company and Dr. Jewell subsequently entered into a separation agreement on October 20, 2025.

Under the agreement, Dr. Jewell released claims through November 14, 2025 in exchange for severance benefits defined in his March 26, 2024 employment agreement, including 12 months of salary and eligibility for a pro‑rated bonus. The separation agreement will be filed with the company’s Annual Report on Form 10‑K for the year ending December 31, 2025.